Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma

Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
Geoffrey ChuppFrank Trudo

Abstract

Benralizumab is a unique eosinophil-depleting monoclonal antibody that significantly reduces asthma exacerbations, improves lung function and asthma symptoms, and permits the reduction of maintenance oral corticosteroid dosage for patients with severe, uncontrolled eosinophilic asthma. To assess benralizumab's onset of action and efficacy by examining change in morning peak expiratory flow (PEF) after initiation of treatment in the phase 3 clinical trials SIROCCO, CALIMA, and ZONDA. Mixed-model repeated-measures analysis was used to calculate PEF using daily least squares mean changes from baseline in morning PEF as well as differences between the benralizumab every 8 weeks (first 3 doses every 4 weeks) and placebo groups. A Bayesian nonlinear mixed-effects approach with an exponential relationship was used to model trial data to determine time to clinically meaningful improvement in morning PEF (defined as ≥25 L/min). Least squares mean morning PEF improvement from baseline was numerically greater by Day 2 after initiation of benralizumab therapy in all 3 trials. The Bayesian nonlinear mixed-effects model indicated that PEF improvement reached the clinically meaningful threshold within 3 weeks in SIROCCO and CALIMA and 2 weeks...Continue Reading

Citations

Nov 7, 2019·Annual Review of Medicine·Geoffrey Lowell ChuppAnne Mainardi
Jun 3, 2020·Allergy·Ioana AgacheMarek Jutel
Nov 11, 2019·Seminars in Immunopathology·Susetta Finotto
Oct 19, 2020·The Journal of Allergy and Clinical Immunology. in Practice·Ann Chen WuMarcus Shaker
Feb 16, 2021·Internal Medicine·Hiroaki MatsuuraTakuo Shibayama

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
Motohiro Kurosawa, Eijin Sutoh
The Lancet. Respiratory Medicine
Leonardo M Fabbri
JAMA : the Journal of the American Medical Association
© 2022 Meta ULC. All rights reserved